Congratulations to our client Neurocrine Biosciences for appointing Sanjay Keswani as Chief Medical Officer.
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. Our client is dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, they have applied their unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. Neurocrine relentlessly pursues medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science.
C1 Team: Christos Richards, Tom Murphy, James Reynolds, Leo Cain, & Todd Aghazadeh